STZ

LBank Exchange Will List 99Starz (STZ) on May 16, 2023

Retrieved on: 
Sunday, May 14, 2023
Heart, NFT, STZ, Cryptocurrency

Road Town, British Virgin Islands--(Newsfile Corp. - May 14, 2023) - LBank Exchange, a global digital asset trading platform, will list 99Starz (STZ) on May 16, 2023.

Key Points: 
  • Road Town, British Virgin Islands--(Newsfile Corp. - May 14, 2023) - LBank Exchange, a global digital asset trading platform, will list 99Starz (STZ) on May 16, 2023.
  • For all users of LBank Exchange, the STZ/USDT trading pair will be officially available for trading at 9:00 UTC on May 16, 2023.
  • Its native token, STZ, will be listed on LBank Exchange at 9:00 UTC on May 16, 2023, with the goal of expanding its global footprint and supporting the realization of its forward-thinking objectives.
  • At the heart of 99Starz is the Gamefied asset management system that allows users to easily track, manage, and monetize their digital assets in a gamified environment.

Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit

Retrieved on: 
Monday, April 24, 2023
Histology, GMP, JDRF, Partnership, American Diabetes Association, Animal, FSE, IPSC, Diabetes, Workflow, HSCI, Somatostatin, Glucagon, Clinical trial, Survival, NSG, PSH, Doctor of Philosophy, Hypoglycemia, Patient, ILC, Cell, TSX, Mouse, IND, EVO, STZ, Pharmaceutical industry, Vaccine, Medical device, Evotec, T1D

The objective of the partnership is to produce an off-the-shelf, commercially scalable cell therapy treatment, with human testing anticipated to begin in 2024.

Key Points: 
  • The objective of the partnership is to produce an off-the-shelf, commercially scalable cell therapy treatment, with human testing anticipated to begin in 2024.
  • The presentation included an introduction to Evotec’s proprietary GMP process for manufacturing iPSC-derived ILCs for use in Sernova’s Cell Pouch, as well as encouraging results from multiple studies using a standard mouse model of T1D.
  • ILCs implanted into Sernova’s Cell Pouch demonstrated rapid normalization of glycemic control in the streptozotocin (STZ)-induced diabetic NSG (NOD.SCID.IL-2Rgammanull) mouse model.
  • “These results demonstrate that Evotec’s ILCs in the Cell Pouch can become fully functional endocrine islets following implantation, with potency equivalent to human islets.

Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model

Retrieved on: 
Wednesday, April 12, 2023
STZ, ELISPOT, C-peptide, Mouse, Biotechnology, Diabetes, NOD, T1D, Serum, Survival, NSG, Research, Disease, Transplant, HIP, Blood, Animal, Patient, Organoid, Flow cytometry, Science Translational Medicine, Escape Room, Fasting, SANA, PSC, Immunosuppression, IND, NOD mice, Pharmaceutical industry, Vaccine, Autoimmunity

SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Science Translational Medicine has published a paper titled “Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice.” The paper details data from a series of ten in vivo experiments demonstrating the insulin-normalization activity, persistence, immune evasion, and lack of immunogenicity of human hypoimmune-modified islet cells, which cluster into effective endocrine organoids termed “pseudo islets.”

Key Points: 
  • “The Science Translational Medicine paper details data demonstrating that hypoimmune pseudo islets developed with our hypoimmune technology survived and were able to reverse diabetes without any immunosuppression in humanized mice.
  • The survival of the p-islets and their cell composition was assessed in immunocompetent, diabetic allogeneic humanized NSG-SGM3 mice.
  • Wt p-islets could only be recovered on the same day and were fully rejected and dissolved at later time points.
  • To generate a humanized, autoimmune mouse, immune cells and iPSCs were generated from PBMCs collected from a person with type 1 diabetes (T1D).

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, HGF, Dementia, Athira Pharma, Neurotoxin, Communication, Nature, MET, Doctor of Philosophy, Pain, Neuroprotection, Alpha-synuclein, Brain, Neurotoxicity, Patient, Society, Nerve, Hepatocyte growth factor, Neurodegeneration, Research, Diabetic neuropathy, Security (finance), Peripheral neuropathy, STZ, Rotenone, PD, Lewy body, Oxidative stress, Neuron, Investment, Safety, RATS, Pharmaceutical industry, Aroma compound, Birth control, Neuroscience, L. Athira Krishna

BOTHELL, Wash., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced data highlighting the potential therapeutic benefits of enhancing the HGF/MET neurotrophic system in preclinical models of Parkinson’s disease (PD) and diabetic neuropathy. These findings were presented at the Neuroscience 2022 conference, hosted by the Society for Neuroscience.

Key Points: 
  • These findings were presented at the Neuroscience 2022 conference, hosted by the Society for Neuroscience.
  • The data presented at Neuroscience 2022 show that fosgonimeton (ATH-1017) promotes neuroprotection, reduces alpha-synuclein aggregation in vitro, and improves motor performance in animal models of Parkinsons disease.
  • An oral nanosymposium presentation highlighted the neuroprotective effects of fosgonimeton against neuronal damage and motor deficits in preclinical models of Parkinsons disease.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.

ALX Resources Corp. Samples Radioactive Zones at the Sabre Uranium Project, Athabasca Basin, Saskatchewan

Retrieved on: 
Tuesday, October 25, 2022
Lithium, Analysis, Jackie Armstrong-Homeniuk, Tourmaline, Athabasca Basin, SEDAR, Frankfurt Stock Exchange, Gold, Soil, First Nations, Uranium, Qualified person (European Union), Metis, NOS, Draco, Corporate communication, News, Snowbird Tectonic Zone, Government House (Saskatchewan), Metal, National instrument, Nickel, Company, STZ, Denison Mines, SWIR, Jigsaw, Financial statement, Risk, National Instrument 43-101, Public health, Copper, Forward-looking statement, ALX, TSX Venture Exchange, Fond, Board, Radioactive decay, OTC, Mineral, Weather, Project, Javelin, Dietary supplement, Mining, Sabre, BC

In addition, sub-samples were submitted for short-wave infrared spectroscopy (SWIR) analyses to determine the clay signature of the samples.

Key Points: 
  • In addition, sub-samples were submitted for short-wave infrared spectroscopy (SWIR) analyses to determine the clay signature of the samples.
  • Sabre is located along the northern margin of the Athabasca Basin, a dominantly sandstone-infilled basin which unconformably overlies crystalline basement rocks of the Tantato Domain of the Canadian Shield in northern Saskatchewan.
  • Numerous historical uranium showings are found within the STZ, such as the Nisto Mine, Black Lake, and the Fond du Lac Uranium Deposit.
  • Dravite is commonly associated with hydrothermal alteration in the Athabasca Basin and can be found in close proximity to unconformity-type uranium mineralization.

Wedbush Securities Equity Research Welcomes Veteran Consumer Analyst Gerald Pascarelli, CFA® as Senior Vice President, Equity Research, Beverages; Initiates Coverage on CELH, KDP, MNST, PEP, KO, SAM, BFB, STZ, MGPI, TAP, and NAPA

Retrieved on: 
Tuesday, October 11, 2022
Banking, Professional Services, Finance, Constellation, Energy drink, SAM, Business administration, Constellation Brands, NAPA, VP, STZ, Drink, KDP, TAP, PepsiCo, Security (finance), MNST, MGP of Indiana, PEP, Industry, State, Monster Beverage, The Coca-Cola Company, Molson Coors Beverage Company, Associate, Cowen Inc., Equity, State university system, Brown–Forman, Alcoholism, BFB, Financial services, Research, Wedbush Securities

Wedbush Securities , one of the nations leading independent diversified financial services providers, is pleased to announce the appointment of Gerald Pascarelli, CFA as the newest Consumer Equity Research Analyst.

Key Points: 
  • Wedbush Securities , one of the nations leading independent diversified financial services providers, is pleased to announce the appointment of Gerald Pascarelli, CFA as the newest Consumer Equity Research Analyst.
  • Todays actions represent the firms entrance into the beverages equity research sector.
  • Gerald is based in Wedbushs New York office and his Associate, Antoine Legault, is based in the firms Los Angeles headquarters.
  • Our expansion into both the non-alcoholic and alcohol beverage categories builds on the firms growth vision in the consumer vertical.

Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

Retrieved on: 
Thursday, September 22, 2022
Diabetes, Lists of diseases, Disease, Patient, ZDF, CEO, European Association for the Study of Diabetes, STZ, Nasdaq, OGTT, EASD, Association, GLOBE, Pioglitazone, RATS, Cancer, AUC, Pharmaceutical industry, Silk

The presentation highlighted BMF-219s ability to improve pancreatic beta cell area and function in two preclinical rat models of diabetes.

Key Points: 
  • The presentation highlighted BMF-219s ability to improve pancreatic beta cell area and function in two preclinical rat models of diabetes.
  • This data provides further support for the potential of BMF-219 as a long-acting, disease modifying treatment for type 2 diabetes.
  • Today we reported direct evidence of BMF-219s ability to increase beta cell area, another key feature of the novel mechanism.
  • BMF-219 also displayed the ability to restore and preserve beta cell function in various type 2 diabetes models.

Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes

Retrieved on: 
Friday, July 1, 2022
Human body weight, American Diabetes Association, Patient, Glucose, Annual general meeting, European Association for the Study of Diabetes, GLOBE, Rat, 2021 Essex County Council election, Diabetes, C-peptide, ZDF, RATS, Disease, Association, OGTT, Cancer, Lists of diseases, IND, Fasting, Pioglitazone, Nasdaq, Liraglutide, Board, EASD, STZ, Insulin, Method, Pharmaceutical industry, Medical device, Osteopathic medicine in Canada, Glycated hemoglobin, T2DM

Oral Presentations to include additional data not released in the two posters presented at the American Diabetes Association Scientific Sessions on June 4, 2022.

Key Points: 
  • Oral Presentations to include additional data not released in the two posters presented at the American Diabetes Association Scientific Sessions on June 4, 2022.
  • Both presentations highlight BMF-219s robust and prolonged glycemic control, insulin sensitization, and HbA1c reduction in two preclinical rat models of diabetes.
  • These preclinical data support the potential utility of BMF-219 as a novel and acutely dosed oral, long-acting treatment for type 2 diabetes.
  • We are honored to be selected for two oral presentations at the European Association for the Study of Diabetes Annual Meeting.

Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

Retrieved on: 
Saturday, June 4, 2022
Osteopathic medicine in Canada, Lists of diseases, Body size and species richness, OGTT, Type 2 diabetes, ADA, Liraglutide, Animal, Cancer, STZ, American Diabetes Association, Diabetes, Nasdaq, IND, Â, RATS, GLOBE, Patient, Pioglitazone, Insulin, Glycated hemoglobin, ZDF, Board, AUC, Zucker, Glucagon, Pharmaceutical industry

These data suggest BMF-219s potential as an oral, long-acting treatment for type 2 diabetes.

Key Points: 
  • These data suggest BMF-219s potential as an oral, long-acting treatment for type 2 diabetes.
  • A therapy that has the ability to generate glucose responsive beta cells would be a major breakthrough for diabetes patients.
  • Collectively these data demonstrate the novel long-acting potential of BMF-219 as a single agent, oral treatment for type 2 diabetes.
  • Collectively, our data indicate the novel and marked potential of BMF-219 as an oral, long-acting treatment for T2DM.

Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models at ADA 2022

Retrieved on: 
Wednesday, June 1, 2022
Hyperglycemia, Lists of diseases, Observation, T2DM, Research, Degenerative disease, Securities Exchange Act of 1934, Type 2 diabetes, Securities Act of 1933, ADA, Liraglutide, Cancer, STZ, Investor, American Diabetes Association, Diabetes, Nasdaq, IND, U.S. Securities and Exchange Commission, 2021 Essex County Council election, GLOBE, Patient, Insulin, Risk, Natural history, ZDF, SEC, Zucker, Microdeletion syndrome, Pancreas, Pharmaceutical industry, Glycated hemoglobin

BMF-219 improved beta cell function and insulin sensitivity while maintaining its effects without chronic drug exposure during the observation period.

Key Points: 
  • BMF-219 improved beta cell function and insulin sensitivity while maintaining its effects without chronic drug exposure during the observation period.
  • The abstract posted on the ADA website highlights the depth and the durability on HbA1C lowering that BMF-219 achieved preclinically in the Zucker diabetic fatty rat (ZDF) model of diabetes.
  • BMF-219, as a single agent, demonstrated a significant reduction in HbA1C versus liraglutide and strong glucose tolerance and glycemic control.
  • Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.